Document is current
Any future updates will be listed below
-
Authors
Chaib, Selim https://orcid.org/0000-0003-0497-2002
Tchkonia, Tamar https://orcid.org/0000-0003-4623-7145
Kirkland, James L. https://orcid.org/0000-0003-1676-4905
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R37AG13925, R33AG61456, R01AG072301, R01AG61414, P01AG62413, UH3AG56933)
the Connor Fund, Robert J. and Theresa W. Ryan, and the Noaber Foundation.
- License Information
-
More Information
Article History
Received: 4 April 2022
Accepted: 28 June 2022
First Online: 11 August 2022
Competing interests
: T.T. and J.L.K. have a financial interest related to this research, including patents and pending patents covering senolytic drugs and their uses that are held by Mayo Clinic. S.C. has received royalties from Rejuveron Senescence Therapeutics. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with the Mayo Clinic’s conflict of interest policies.
